Yu Wei

Dr. Yu Wei


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Medicine
Verified
Journal Article
Open access
NMNuersimanguli Mm Maimaitiming
Nuersimanguli Mm Maimaitiming
XMXiaoli Ma
Xiaoli Ma
YWYu Wei
Yu Wei
LCLeiyu Mm Cao
Leiyu Mm Cao
YGYan Gao Gao
Yan Gao Gao
LZLi Zhang
Li Zhang
Background: To evaluate the role and safety of endostar in cervical cancer by comparing the efficacy and adverse reactions of endostar combined with concurrent chemoradiotherapy in patients with locally advanced cervical carcinoma. Methods: The quality of the included literature was evaluated by searching the database for the comparison of endostar combined with concurrent radiotherapy and chemotherapy in cervical cancer patients; objective response rate (ORR) and disease control rate (DCR) were used as the main outcome indicators, and statistical analysis was performed using RevMan5.3 and State15.3 software. Results: A total of 13 studies were included in this study, including 1057 patients with locally advanced cervical cancer, suggesting that endostar combined with chemoradiotherapy can significantly improve the objective response rate (ORR: odds ratio 3.88, 95% confidence interval 2.77–5.45, P < .00001) and disease control rate (DCR: odds ratio 4.43, 95% confidence interval 2.78–7.04; P < .00001), and there was no significant increase in treatment-related adverse reactions. Conclusions: In this meta-analysis, endostar combined with concurrent chemoradiotherapy significantly improved ORR and DCR in patients with locally advanced cervical cancer without increasing toxicity. However, this study only analyzed the short-term efficacy of endostar, and its influence on overall survival and progression-free survival needs to be further verified in large randomized controlled trials with long-term follow-up.

15 August 2025 in Medicine
Verified
Journal Article
Open access
MHMuhetaibaier Hairoula
Muhetaibaier Hairoula
YWYu Wei
Yu Wei
KMKalima Muhetaer
Kalima Muhetaer
XMXiaoli Ma
Xiaoli Ma
LCLeiyu Cao
Leiyu Cao
LZLi Zhang
Li Zhang
Background: The advent of immune checkpoint inhibitors has introduced innovative therapeutic paradigms for the management of human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction cancer (GC/GEJC). However, the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy versus chemotherapy alone in patients with HER2-negative advanced GC/GEJC remain contentious. The comparability among different subgroups is not fully understood, necessitating the identification of optimal patient demographics and the exploration of potential biomarkers. Methods: This study identified 6 Phase III randomized controlled trials evaluating the first-line treatment of HER2-negative GC/GEJC with PD-1 inhibitors in combination with chemotherapy. The primary endpoints include overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), assessed using hazard ratios (HR), relative risk, and their respective 95% confidence intervals (CI). Secondary outcomes are treatment-related adverse events and immune-related adverse events. Prespecified subgroups encompass microsatellite instability, programmed death-ligand 1 (PD-L1) combined positive score (CPS), age, gender, previous surgery, primary location, liver metastases, Eastern Cooperative Oncology Group performance status score, histological subtype, chemotherapy regimen, race, and PD-L1 expression in tumor cells. Results: Incorporating data from 6 randomized controlled trials, this analysis included 6294 adult patients with HER2-negative advanced GC/GEJC. The combined PD-1 inhibitor and chemotherapy regimen significantly improved OS ( HR = 0.79, 95% CI [0.75, 0.84], P < .00001) and PFS ( HR = 0.75, 95% CI [0.70, 0.80], P < .00001), along with enhancing the ORR (relative risk = 1.22, 95% CI [1.15, 1.29], P < .00001). Subgroup analyses revealed benefits in OS, PFS, and ORR for patients with CPS ≥ 1, CPS ≥ 5, and CPS ≥ 10 when treated with first-line PD-1 inhibitors and chemotherapy, with higher PD-L1 expression levels correlating with greater efficacy. Furthermore, patients with high microsatellite instability exhibited a more pronounced extension in OS ( HR = 0.35, 95% CI [0.21, 0.59], P < .0001). However, factors such as age, gender, previous surgery, primary location, liver metastases, Eastern Cooperative Oncology Group performance status score, histological subtype, chemotherapy regimen, race, and PD-L1 expression in tumor cells were not predictive of an OS benefit from PD-1 inhibitors combined with chemotherapy over chemotherapy alone. Regarding safety, the PD-1 inhibitor and chemotherapy combination led to a higher incidence of immune-mediated adverse events, though there was no significant difference in adverse events leading to death. Conclusion: First-line treatment with PD-1 inhibitors combined with chemotherapy surpasses chemotherapy alone in efficacy for patients with HER2-negative advanced GC/GEJC, particularly in those with CPS ≥ 10 or high microsatellite instability, with tolerable adverse events.

21 July 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YWYu Wei
Yu Wei
JLJuan Liu
Juan Liu
YGYan Gao
Yan Gao
XMXiaoli Ma
Xiaoli Ma
LCLeiyu Cao
Leiyu Cao
LZLi Zhang
Li Zhang
Objective. Esophageal squamous-cell carcinoma (ESCC) is an aggressive malignant tumor, accounting for more than 90% of esophageal cancers. However, treatments such as surgical resection, radiotherapy, and chemotherapy are unable to achieve ideal clinical outcomes. The purpose of this study was to explore the effects of COQ10B on proliferation, apoptosis, migration, and invasion of esophageal squamous-cell carcinoma (ESCC) cells. Methods. Quantitative real-time PCR (qRT-PCR) was used to detect the expression of COQ10B in ESCC and normal tissues and in ESCC cell lines (KYSE-15 and TE-1). MTT assay and flow cytometry were applied to investigate the effects of COQ10B shRNA lentivirus (LV-shCOQ10B) on ESCC cell proliferation and apoptosis, respectively. The effect of COQ10B silencing on ESCC cell migration and invasion was determined by wound healing assay and transwell invasion assay, respectively. Results. The expression of COQ10B mRNA in ESCC tissues was higher than that in surrounding tissues. The decreased COQ10B level in KYSE-15 and TE-1 cells by LV-shCOQ10B could inhibit cell proliferation, promote cell apoptosis, and reduce the ability of invasion and migration (all ). Conclusion. COQ10B was highly expressed in human ESCC tissues. COQ10B silencing contributed to the inhibition of proliferation, invasion, and migration of ESCC cells and the promotion of cell apoptosis, suggesting COQ10B may be a potential molecular target for the diagnosis and treatment of ESCC.